CrossrefInfokarte
Octapharma’s balanced portfolio built on a very special juice
The Journal of Haemophilia Practice · 2013
DOI: 10.17225/jhp.00023 ↗Abstract
Abstract Octapharma's core business is the development and production of human proteins from human plasma and cell lines. As the company moves into the recombinant arena, Chairman Wolfgang Marguerre discusses opportunities and threats with Editor-in-Chief Kate Khair
EUVIMED